Status:
UNKNOWN
How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?
Lead Sponsor:
Christchurch Hospital
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Pioglitazone is an insulin sensitising drug used in the treatment of patients with type 2 diabetes. In addition to its blood sugar lowering effect, pioglitazone also has a number of other beneficial e...
Detailed Description
In addition to their insulin sensitising action, thiazolidinediones (TZDs) have beneficial effects on vascular function. These include a decrease in proteinuria and amelioration of diabetic nephropath...
Eligibility Criteria
Inclusion
- Diabetes mellitus, Type 2
- Age 18-70 yrs
Exclusion
- Overt proteinuria (urine albumin:creatinine ratio \>10.0
- Plasma creatinine 0.15 mmol/L
- HbA1c \>10%
- Hear failure Class III or IV
- Peripheral oedema
- Abnormal liver function (serum AST \>2.5 times upper limit of normal)
- Pregnancy or breastfeeding
- History of urinary tract infections
- Serious concomitant disorder
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00749047
Start Date
September 1 2008
End Date
March 1 2010
Last Update
September 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Christchurch Hospital
Christchurch, Canterbury, New Zealand, 8001